Draft Guidance On Developing Drug Names Calls For Simulation Studies
This article was originally published in The Tan Sheet
FDA’s draft guidance on developing proprietary drug names recommends steps to evaluate a proposed name, including testing names with health care professionals. The draft notes that OTC “brand name extensions have posed problems when the same root proprietary name is used for multiple products.”
You may also be interested in...
The pharmaceutical industry wants FDA to prove its proprietary name review program is worth the effort.
FDA's request that Novartis rebrand a Maalox line extension is the latest illustration of the agency taking action based on a relatively small number of serious adverse event reports
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.